PRMT5 and neoplasm: Given the development of pre-clinical small molecules targeting PRMT5, combination treatment of PRMT5 inhibitors, along with conventional chemotherapy enabling tumor de-bulking, could have a significant impact on long-term outcomes for breast cancer patients.